Background: Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies
Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies defi ned by an ineffective, dysplastic bone marrow that produces an insuffi cient quantity of functional blood cells. 1 The resultant cytopenias and clinical manifestations characterize a variety of subclasses. Survival in MDS ranges from a median of 5.7 years in lower-risk patients to as little as 0.4 years in higher-risk patients. 2 Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell (RBC) transfusions. In approximately 30% of cases, 3 MDS can also transform to acute myeloid leukemia (AML).
The estimated annual age-adjusted incidence rate of MDS in the United States is 3.4 cases per 100,000 individuals, with approximately 10,000 new cases per year. 4, 5 Considering the aging population, this fi gure will likely grow as MDS malignancies are common in patients over 60 years of age. 6 Furthermore, many patients wait for years to be correctly diagnosed. 7 Despite previous debate regarding MDS as cancers, these syndromes have been included in reports from the Surveillance, Epidemiology and End Results (SEER) Program since 2002. 8, 9 It was during that time that the most recent disease classifi cation published by the World Health Organization (WHO) clearly designated the syndromes as hematopoietic neoplasms.
Nevertheless, the stringency of the diagnostic criteria may underrepresent the true extent of MDS as reported by the SEER Program and, in some cases, make them diffi cult to diagnose. Furthermore, analysis of Medicare claims data suggests that the num-ber of MDS patients may be higher than reported. 11 Signifi cant advances in the treatment of MDS have been made in the past decade. The US Food and Drug Administration has now approved several disease-specifi c agents including hypomethylating agents (azacitidine and decitabine), and the immunomodulatory agent lenalidomide, indicated for the treatment of patients with low-risk MDS harboring the del(5q) chromosomal abnormality. 7 Given these considerations, a closer examination of present educational needs involving MDS was undertaken to identify educational gaps and develop educational activities that will improve the identifi cation and care of patients with this group of malignancies.
Methods
During October of 2009, a multidisciplinary panel was convened to examine professional education needs regarding the diagnosis and care of patients with MDS. Participants included a community-based internal medicine specialist, one community-based and two academic hematologists/oncologists, an oncology nurse, representatives from the Aplastic Anemia & MDS International Foundation and the MDS Foundation, and continuing medical education (CME) and communication providers with MDS experience.
A process for collecting and evaluating panel member input and documentary evidence was set forth prior to this meeting (Fig 1) . All 10 members of the panel were surveyed via e-mail to defi ne their top three MDS educational needs approximately 1 month before the panel gathered and were asked to provide relevant documentary support (Table 1) . These data were organized to structure the discussion and to provide further support to the observations and recommendations made by the panel.
During the meeting, a group consensus approach utilizing a modifi ed nominal group technique 12 was employed to prioritize needs identifi ed in the pre-meeting survey. After ranking the needs shared with the group, participants discussed each in detail, examined supportive evidence, proposed strategies, and discussed future program approaches for consideration.
Results
Of the 10 panel members surveyed, seven responded. These included two academic hematologist/oncologists, one oncology nurse, one representative from an MDS advocacy group, and three CME and communication providers.
Through the survey, the panel identifi ed a number of educational needs relevant to MDS that included (1) MDS disease awareness, (2) diagnosis, (3) classifi cation and risk stratifi cation, (4) treatment issues, (5) referral to stem cell transplantation or new treatment protocols, (6) clinical monitoring and toxicity management, and (7) translation of new data into patient care (Tables 2-5) . During the meeting, the panel offered recommendations based on audience type (Table 6 ). These were examined in detail to better defi ne areas for educational focus.
Disease Awareness
The panel noted a strong need to create awareness about MDS among several medical specialties based on needs and gaps listed in Table 2 . The internal medicine specialist indicated that primary care physicians (PCPs), who act as gatekeepers for many patients, do not commonly consider a diagnosis of MDS or bone marrow failure syndrome as an underlying cause of anemia. PCPs will more likely refer an anemic patient to a gastroenterologist to rule out gastrointestinal bleeding, a more common etiology and acute medical situation. 13 The PCP may not consider a diagnosis or referral of a patient with suspected MDS because these malignancies are uncommon in the population overall. Therefore, creating awareness is critical to allow for the inclusion of MDS in the differential diagnosis of chronic anemia so that PCPs can consider referring such patients to a hematology or oncology specialist.
Furthermore, community-based hematologist/oncologists see only a limited number of MDS patients each year. One survey reported that 63% of 92 communit hema- 
Diagnosis
A related educational need involved MDS diagnosis, as highlighted in Table 2 . The panel observed that ruling tologists/oncologists saw between 0 and 10 new MDS patients annually. 14 Thus, given the low incidence of MDS, awareness of the disease is essential in arriving at a correct diagnosis.
The panel pointed out the importance of optimizing continuing medical education (CME) platforms, especially for PCPs and pathologists, regarding anemia and malignant hematology for general medicine. An ideal program would review chronic anemia in the elderly by examining (1) the etiologies of chronic anemia, (2) out bone marrow failure or dysfunction was not a priority among community physicians in the management of anemic patients. Referral of an anemic patient to a hematologist occurred more often after complications ensued (eg, development of other cytopenias, infection, bleeding, or increasing transfusion requirements). The evaluation of peripheral smears in patients with cytopenias can provide valuable clues for the diagnosis or the need for additional workup such as performing a bone marrow biopsy to further investigate the cause of cytopenias. One hematologist recommended that examination of a peripheral blood smear by a pathologist could be incorporated into the anemia management guidelines for general medicine. 15 To help practitioners perform a viable initial evaluation, education activities should focus on proper workup of anemic or cytopenic patients including (1) patient history and physical examination, (2) diagnostic tests such as complete blood count (CBC) with differential, reticulocyte count, (3) peripheral smear examination, (4) bone marrow aspiration with iron stain, biopsy, and cytogenetics, (5) serum erythropoietin level (prior to RBC transfusion or erythropoietin administration), (6) RBC folate and serum B 12 , serum ferritin, serum iron, and total iron-binding capacity, and (7) transfusion history. 1 The panel members also expressed the need for community-based hematology/oncology specialists to be fully aware of the latest National Comprehensive Cancer Network (NCCN) diagnostic guidelines for MDS (Fig 2) . These specialists may benefi t from educational activities addressing proper workup, evaluation, and staging of their MDS patients. Based on the NCCN guidelines, some of the diagnostic criteria require more in-depth tests and expertise in review. 1 Awareness of these tests and knowledge of where and when to refer for additional expertise are critical elements in establishing an appropriate diagnosis. Therefore, CME programs should focus on these issues to strengthen practitioner knowledge and application of these guidelines.
Since hematology/oncology practitioners receive multiple test reports, they may fi nd it diffi cult to efficiently integrate requisite information to help make an MDS diagnosis. The group felt that it would be ideal if laboratories were to develop a comprehensive report or some other mechanism (eg, electronic medical record) to consolidate these data into a central accessible point that would facilitate accurate diagnoses in a timely manner. Educational programs could then incorporate examples of these improved forms of delivery with the objective that practitioners would integrate them into their practices. Educational programs, particularly for general practitioners and community hematologists/oncologists, should also address the changes that occur over time in CBCs and provide practical triggers (eg, age over 70 years, clinically signifi cant changes in laboratory values) for initiation of workup or consideration of a referral.
An educational gap surrounding the diagnosis of MDS was identifi ed for pathologists. Increasing awareness and education among pathologists regarding prerequisites for the diagnosis of this entity could help ensure proper identifi cation of MDS when a peripheral smear or bone marrow specimen is submitted for evaluation.
Educational programs for these practitioners should focus on creating awareness of MDS and criteria for making an accurate diagnosis. Content should identify triggers for evaluating peripheral smears and improving the identifi cation of dysplastic cells. One initiative involved an online virtual microscopy CME training program to increase concordance in the reading and evaluation of cytopenias and peripheral smears to ensure that all MDS patients receive a correct morphologic diagnosis.
16
Finally, pathology education should include hematopathology reports with integrated morphology, cytogenetics, fl ow cytometry, and molecular tests to facilitate correct diagnosis/classifi cation and better understanding of disease biology.
Classifi cation and Risk Stratifi cation
The availability of multiple classifi cation and risk stratification systems for MDS can lead to confusion. The two classifi cation systems used to categorize MDS include the French-American-British (FAB) 17 and the World Health
Organization (WHO). 9 Systems used to assist in predicting survival and the risk of leukemia evolution of MDS patients include the International Prognostic Scoring System (IPSS), 2 noted by the panel as the most commonly used system, 18 and the WHO-based Prognostic Scoring System (WPSS). 19 Education should cover risk stratifi cation of MDS so that practitioners can properly plan treatment in line with addressing the needs listed in Table 2 . The panel noted that hematology/oncology specialists may also benefi t from applying the NCCN recommendations for scoring and determining prognosis. Educational activities may also include information on how to utilize the most common system, the IPSS. While existing scoring systems are not perfect, they are commonly applied in risk stratifi cation and for inclusion in clinical trials. Therefore, awareness of the benefi ts and pitfalls of such systems is essential in selecting therapies and understanding clinical trial data.
Hematologists/oncologists may benefi t from a better understanding of the impact of transfusion dependency and cytogenetics on the risk and prognosis of their MDS patients. The panel believed that training should incorporate the diagnostic algorithms recommended by the NCCN and should focus on the impact of these parameters on risk and prognosis.
Panel participants also noted that practitioners need to implement recommended diagnostic testing to accurately calculate an appropriate IPSS staging score. In a recent practice survey, the MDS Foundation noted a disparity among specialists (ie, hematologist vs pathologist) based on who calculates the IPSS. 1 Interestingly, the community-based hematology/oncology specialist on the panel emphasized that education should involve a "quick and simple" approach to calculate an IPSS risk score in 3 minutes or less. Finally, educational programs should reinforce importance of the pathologist and the hematologist/oncologist working as a team to ensure consistency in testing and evaluating for proper diagnosis and staging.
Treatment Issues
The panel identifi ed a number of critical issues for hematology/oncology specialists related to treatment (Table 3) : (1) when to treat MDS, (2) what treatment to use initially, (3) when to initiate a disease-modifying treatment, (4) what is the optimal duration of therapy, (5) what is considered a treatment success/failure, and (6) how to manage side effects to optimize duration of treatment and potential outcomes.
In discussing when to treat MDS, the panel noted that many community-based practitioners take a "watch and wait" approach using best supportive care (BSC), such as transfusions, hematopoietic growth factors, and antibiotics, for the treatment of their lower-risk MDS patients for as long as 13 to 20 months. 20 The decision to use supportive care may be due to an older patient population, the lack of overt signs and symptoms, and the existence of comorbid conditions. Chronic RBC transfusions are often chosen for initial treatment, especially for elderly patients. 1, 21 The panel advised that practitioners may benefi t from educational programs that not only discuss the potential morbidity and mortality risks associated with chronic RBC transfusion dependency and iron overload, 22 but also address ongoing clinical trials to evaluate how mitigating these risk factors may infl uence survival. 23 Nevertheless, education should address the implications of the commonly used "watch and wait" approach and address the role that newer disease-specifi c agents may have in these patients.
Participants noted a recent trend in the treatment of lower-risk MDS patients is transitioning from a supportive care approach to one that focuses on altering the natural history of the disease (eg, overall survival). This direction, based on recent data concerning therapy with hypomethylating agents (specifi cally azacitidine), is particularly relevant in the intermediate-2 and higherrisk patient populations, but it has not yet been proven to exert the same survival benefi t in a lower-risk patient population.
25,26 Educational efforts should focus on treatment goals, considering the availability of therapies that can reduce transfusion needs or produce a cytogenetic response. 25 Regarding the initial treatment of MDS, today's hematology/oncology practitioners have several options beyond transfusions and BSC: (1) erythropoietin-stimulating agents (ESAs), which some specialists consider as BSC, (2) hypomethylating agents, and (3) immunomodulatory agents. Educational initiatives focused on clarifying when to initiate therapy beyond BSC and transfusions and when to recommend individualized therapy based on risk would be important to consider. Due to copyright restrictions, this fi gure has been removed from this online article.
The panel suggested that educational activities incorporate a simple decision-based fl ow chart, as outlined in the NCCN Practice Guidelines. 1 ESAs, including recombinant human erythropoietin and darbepoetin alfa, are commonly used as MDS therapy. This fi nding is consistent with a 2008 survey of community hematology/oncology practitioners in which 51% of participants indicated that they have used these agents for the treatment of MDS. 20 Educational programs should address the following issues: (1) 
The panel extensively reviewed the role of diseasemodifying treatments (eg, hypomethylating and immunomodulatory agents). One survey pointed out that disease-modifying treatments, such as hypomethylating agents, were primarily used in higher-risk patients despite having been approved in 2004 for a broader range of MDS patients. 20 The panel raised the question as to whether such therapy should be relegated to only this population despite evidence-based data regarding its benefi t for patients with lower-risk disease. Practitioners may benefi t from a deeper understanding of critical data supporting the use of these agents and their role in therapy. Lenalidomide has yielded prolonged and sustained cytogenetic/hematologic improvement, particularly in del(5q) patients. 26 Azacitidine has been shown to statistically improve overall survival in higher-risk patients, 6 and decitabine has also been associated with responses and transfusion independence. 27 The panel identifi ed the need to better understand what clinical or pathologic triggers should be used to initiate the use of these agents in MDS patients. As cited by the panel, educational programs should emphasize four main scenarios for starting one of these agents: (1) symptomatic, clinically signifi cant anemia (Ͻ 10 g/dL) 1 or transfusion dependence (defi ned as one RBC transfusion every 8 weeks over a period of 4 months), 18 (2) cytogenetic test results, (3) the presence of intermediate-2 or high-risk MDS, and (4) clinically signifi cant neutropenia or thrombocytopenia.
Results from recent clinical trials have fostered a reassessment of response rates as the primary endpoint and other important clinical endpoints (eg, prolonged time to leukemic transformation and increased overall survival) to defi ne treatment success. 28 The panel identifi ed two gaps to be addressed in education regarding response: (1) the criteria that should be used to defi ne success (response rates, clinical response, cytogenetic response survival) and (2) the time period over which these criteria should be evaluated.
As clinical trial data may not be entirely applicable to the patient seen in the clinic by a hematology/oncology practitioner, the panel also suggested that educational efforts should involve a number of practical considerations specifi c to scheduling and dosing of therapy to improve outcomes. Content should focus on (1) determining when disease-modifying treatment should be initiated/ stopped, (2) clarifying optimal treatment duration and the number of treatment cycles, (3) examining the pros and cons of varying dosing schedules or routes (intravenous or subcutaneous) that balance patient convenience with clinical effi cacy, (4) optimizing management of hematologic and other toxicities associated with the use of these agents, and (5) determining the impact of organ dysfunction on toxicity and potential need for dose modifi cation, as would be considered with renal and hepatic dysfunction.
Referring Patients for Hematopoietic Stem Cell Transplantation or New Treatment Protocols
A survey of hematologists in the community reported that approximately 4% of patients have been considered for hematopoietic stem cell transplantation (HSCT), the only curative therapy for MDS. 20 In addition, only 1% of recently diagnosed MDS patients and 1% to 4% of established MDS patients were considered for clinical trials. 20 One participant noted that community practitioners may feel that referral for HSCT or a clinical trial may be akin to declaring failure. Patients have often been excluded from HSCT and clinical trial protocols due to factors such as age and comorbidities, and referral of adult patients into clinical trials has been low across all oncology indications. 27 There was strong consensus among the panel members for education that focuses on the role and value of HSCT and clinical trial protocol options in line with the needs identifi ed in Table 3 . A main objective for these programs would be to emphasize the collaboration between community practitioners with medical centers that possess extensive MDS experience in order to qualify, prepare, and comanage these patients. This type of approach would help to facilitate additional referrals of appropriate patients in trials of HSCT.
Clinical Monitoring and Treatment-Related Toxicity Management
Monitoring for response and safety and balancing toxicity with response were two important gaps discussed, as noted in Table 4 . Treating physicians should be aware of what endpoints to monitor, and over what time period, in order to assess response and manage toxicity. For example, the initial cytopenias seen with agents such as lenalidomide may provide an initial indication of eventual improvement. 29 It is not uncommon for practitioners to cease treatment after one or two courses of a diseasespecifi c treatment (eg, lenalidomide, hypomethylators) in the face of cytopenias and patient complaints due to an overriding desire to "do no harm" in MDS patients who are older and more fragile. 21 Educational objectives for programming should focus on cytopenia: (1) its effect of treatments, (2) its relationship to response, and (3) strategies such as dose reduction, growth factor, and blood product support for assisting patients through the fi rst few critical cycles. Practitioners should be aware of the number of treatment cycles and supportive care strategies to optimize cycles and outcomes. Through optimal dosing, MDS can be treated for longer periods of time with fewer adverse events so patients can derive maximum clinical benefi t. 30, 31 The panel believed the target audience for these educational initiatives should include both hematologists/oncologists and oncology nurses.
Management of patient expectations was another educational need identifi ed in this section. Based on its online survey of patients in March 2009, the Aplastic Anemia & MDS International Foundation found patient education to be an important issue. 7 The panel pointed out that health care provider and patient behavior need to change relative to treatment expectations. Patient education should reinforce that (1) MDS is a type of malignancy, (2) treatment is needed, and (3) effective, disease-specifi c therapies are available. Furthermore, CME activities should help practitioners in their discussion with patients regarding treatment side effects. Suggested topics could include (1) the initial effect of some treatments (ie, lenalidomide, hypomethylators) on the bone marrow and blood counts, (2) strategies to manage these effects, (3) the importance of completing the fi rst few cycles for best possible response, and (4) the length of treatment to determine effi cacy. 25 Educational programs should include patient-friendly tools to help explain to patients the signifi cance of blood counts and how they can best be managed.
Finally, the panel emphasized that educational programs should recognize the importance of the oncology nurse in addressing patient concerns and assisting in the management of the clinical and psychosocial aspects of treatment toxicity. The role of the nurse is critical in providing support to patients as they deal with treatment side effects.
Translation of New Clinical Trial Data Into Patient Care
The panel highlighted the need to promptly translate guidelines and clinical trial data (phase II and III) into clinical practice as noted in Table 5 . A survey of 275 community oncologists found that practitioners faced challenges not only in providing evidence-based care that incorporates new treatments in an increasingly diffi cult reimbursement environment, but also in devoting the necessary time to remain up to date in an environment of limited educational opportunities (compared with those in an academic setting). According to the survey (P. R., unpublished data, 2009), the primary educational methods used by community practitioners included attending professional society meetings, participating in informal discussions with colleagues, and taking part in tumor board/case-based interactive programs.
The panel pointed out that educational programs need to communicate results from clinical trials into the standard armamentarium used by community hematologists/oncologists so patients receive state-of-the-art care to improve outcomes. Not all practitioners have access to the newest clinical trial data as many community practitioners may not attend national meetings where the latest research is often presented. One suggestion to overcome this lapse was to share highlights (eg, the Best of ASH/ASCO, MedscapeCME Oncology Insights, NCI-ASCO, ASH Highlights) that focus on anemia and malignant hematology for both hematology/oncology and general medicine practitioners who cannot or do not attend. [32] [33] [34] [35] This information can be disseminated through a variety of educational media including audio, Internet, and print.
Finally, the panel underscored the importance of translating practice-changing clinical data presented at major meetings into practical information for use in the community setting. These issues might focus on patient selection, dosage, administration, monitoring, and reimbursement.
Communication and Education Strategies
The panel recommended that educational strategies should embrace a diverse mix of activities and formats including live presentations, Web casts, print articles, point-of-care education, and radio broadcasts. Programs should also tie into point-of-care resources (eg, UpToDate 36 or ClinicalCareOptions 37 ) already being used by practitioners. Interestingly, one needs assessment noted that hematologists/oncologists obtained their information from conferences, peers, and tumor boards. 31 This observation reinforces the need for live, peer-to-peer programming in the form of conferences, dinner meetings, consultations, or Webinars.
In addition to providing current clinical data from major meetings, practitioners within the group emphasized the importance of integrating clinical cases. The academic participants concurred with this suggestion and reported that they were incorporating more case examples into their presentations to community-based audiences.
Finally, the panel noted that educational programs should focus on key content areas and be repetitive. Members felt that short-contact programs (0.25 and 0.5 credit hours) may be more attractive and effective. The panel also recommended that educational programs need to adjust to the needs of the target audience as specifi c health care professionals require different approaches and educational emphasis (Table 6 ).
Conclusions
MDS is a diverse collection of uncommon hematologic malignancies that often present as anemia. It may not be fully recognized as a malignant disorder, thus resulting in a delay in diagnosis or in underdiagnosis of this cancer. Changes have occurred over the last decade regarding the characterization and classifi cation of MDS, along with the approval of several new disease-specifi c treatments. Due to these developments, signifi cant needs exist for further professional education to create awareness regarding the disease, the timely and accurate diagnosis and staging of MDS, and appropriate treatment strategies. Educational programs should be tailored for the intended audience (eg, general medicine, hematology/oncology practitioners, oncology nurses) with current information from major meetings and guideline recommendations. The education provided should be practical and easily applied by community-based practitioners. Hopefully, these observations and recommendations will stimulate further discussion and the development of educational programming that will improve the identifi cation and care of MDS patients.
